• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

基于HIV多表位和p24蛋白的重组DNA疫苗和重组禽痘病毒疫苗联合免疫中国恒河猴预防SHIV-KB9感染

Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.

作者信息

Li Chang, Shen Zhenwei, Li Xiao, Bai Jieying, Zeng Lin, Tian Mingyao, Song Ying Jin, Ye Ming, Du Shouwen, Ren Dayong, Liu Cunxia, Zhu Na, Sun Dandan, Li Yi, Jin Ningyi

机构信息

Institute of Military Veterinary Medicine, Academy of Military Medical Sciences, LiuYingXi Road No. 666, Changchun 130122, China.

出版信息

Clin Dev Immunol. 2012;2012:958404. doi: 10.1155/2012/958404. Epub 2012 Feb 26.

DOI:10.1155/2012/958404
PMID:22474488
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3299295/
Abstract

Developing an effective vaccine against HIV infection remains an urgent goal. We used a DNA prime/fowlpox virus boost regimen to immunize Chinese rhesus macaques. The animals were challenged intramuscularly with pathogenic molecularly cloned SHIV-KB9. Immunogenicity and protective efficacy of vaccines were investigated by measuring IFN-γ levels, monitoring HIV-specific binding antibodies, examining viral load, and analyzing CD4/CD8 ratio. Results show that, upon challenge, the vaccine group can induce a strong immune response in the body, represented by increased expression of IFN-γ, slow and steady elevated antibody production, reduced peak value of acute viral load, and increase in the average CD4/CD8 ratio. The current research suggests that rapid reaction speed, appropriate response strength, and long-lasting immune response time may be key protection factors for AIDS vaccine. The present study contributes significantly to AIDS vaccine and preclinical research.

摘要

开发一种有效的抗HIV感染疫苗仍然是一个紧迫的目标。我们使用DNA初免/禽痘病毒加强免疫方案对中国恒河猴进行免疫。动物通过肌肉注射致病性分子克隆的SHIV-KB9进行攻击。通过测量IFN-γ水平、监测HIV特异性结合抗体、检测病毒载量以及分析CD4/CD8比值来研究疫苗的免疫原性和保护效果。结果显示，在攻击后，疫苗组可在体内诱导强烈的免疫反应，表现为IFN-γ表达增加、抗体产生缓慢且稳定升高、急性病毒载量峰值降低以及平均CD4/CD8比值增加。当前研究表明，快速的反应速度、适当的反应强度和持久的免疫反应时间可能是艾滋病疫苗的关键保护因素。本研究对艾滋病疫苗及临床前研究有显著贡献。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/f678dab5067d/CDI2012-958404.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/cf2fa1fa66ac/CDI2012-958404.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/ccc0282a0b9e/CDI2012-958404.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/3d45c2e770c0/CDI2012-958404.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/8c0eadb3efd8/CDI2012-958404.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/f678dab5067d/CDI2012-958404.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/cf2fa1fa66ac/CDI2012-958404.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/ccc0282a0b9e/CDI2012-958404.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/3d45c2e770c0/CDI2012-958404.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/8c0eadb3efd8/CDI2012-958404.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9780/3299295/f678dab5067d/CDI2012-958404.005.jpg

相似文献

1
Protection against SHIV-KB9 infection by combining rDNA and rFPV vaccines based on HIV multiepitope and p24 protein in Chinese rhesus macaques.基于HIV多表位和p24蛋白的重组DNA疫苗和重组禽痘病毒疫苗联合免疫中国恒河猴预防SHIV-KB9感染
Clin Dev Immunol. 2012;2012:958404. doi: 10.1155/2012/958404. Epub 2012 Feb 26.
2
Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3.经黏膜给药的人猿免疫缺陷病毒DNA和基于鸡痘病毒的重组疫苗，可降低猕猴经阴道接种CCR5嗜性SHIVSF162P3后急性期的病毒复制。
Vaccine. 2005 Oct 10;23(42):5009-21. doi: 10.1016/j.vaccine.2005.05.032.
3
Efficacy of DNA and fowlpox virus priming/boosting vaccines for simian/human immunodeficiency virus.DNA和禽痘病毒初免/加强疫苗对猿猴/人类免疫缺陷病毒的疗效。
J Virol. 2004 Dec;78(24):13819-28. doi: 10.1128/JVI.78.24.13819-13828.2004.
4
Protective effects of nef-deleted SHIV or that having IFN-gamma against disease induced with a pathogenic virus early after vaccination.缺失nef的猿猴/人免疫缺陷病毒嵌合体（SHIV）或具有γ干扰素的SHIV在疫苗接种后早期对致病性病毒诱导疾病的保护作用。
Arch Virol. 2004 Sep;149(9):1705-20. doi: 10.1007/s00705-004-0333-8.
5
Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.用表达 HIV-1 病毒样颗粒的 DNA 和重组痘病毒载体对中国食蟹猴进行异源初免-加强-加强免疫接种。
Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429.
6
Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239.用DNA初免/改良安卡拉痘苗病毒加强免疫方案对恒河猴进行免疫，可诱导广泛的猿猴免疫缺陷病毒（SIV）特异性T细胞反应，并减少初始病毒复制，但不能预防致病性SIVmac239攻击后疾病的进展。
J Virol. 2002 Jul;76(14):7187-202. doi: 10.1128/jvi.76.14.7187-7202.2002.
7
Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.用重组卡介苗（Mycobacterium bovis bacillus Calmette-Guérin）Env V3免疫恒河猴，可引发中和抗体介导的针对猿猴-人类免疫缺陷病毒的保护作用，该保护作用针对具有同源而非异源V3基序的病毒。
J Virol. 2005 Feb;79(3):1452-62. doi: 10.1128/JVI.79.3.1452-1462.2005.
8
Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.用人类免疫缺陷病毒 1 糖蛋白 gp41 中的保守 caveolin-1 结合基序进行免疫接种可延迟病毒感染的发作，并为感染猴免疫缺陷病毒的食蟹猴提供部分保护。
J Virol. 2018 Aug 29;92(18). doi: 10.1128/JVI.00370-18. Print 2018 Sep 15.
9
Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge.人类免疫缺陷病毒 C.1086 包膜 gp140 蛋白增强剂在 DNA/改良安卡拉牛痘病毒疫苗接种后未能增强针对 V1V2 抗体的异源反应和对 C 型猴免疫缺陷病毒攻击的保护。
J Virol. 2019 Sep 30;93(20). doi: 10.1128/JVI.00934-19. Print 2019 Oct 15.
10
Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates.非人灵长类动物经白细胞介素-2增强的DNA修饰安卡拉痘苗病毒鼻腔接种后猿猴/人类免疫缺陷病毒血症及疾病进展的控制
J Immunol. 2004 Mar 15;172(6):3745-57. doi: 10.4049/jimmunol.172.6.3745.

引用本文的文献

1
Overcoming immunogenicity issues of HIV p24 antigen by the use of innovative nanostructured lipid carriers as delivery systems: evidences in mice and non-human primates.通过使用创新的纳米结构脂质载体作为递送系统克服HIV p24抗原的免疫原性问题：小鼠和非人灵长类动物的证据。
NPJ Vaccines. 2018 Oct 1;3:46. doi: 10.1038/s41541-018-0086-0. eCollection 2018.
2
A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.一项关于通过电穿孔接种的EP - 1300多表位DNA疫苗抗恶性疟原虫疟疾的1期随机对照剂量递增研究。
Vaccine. 2016 Nov 4;34(46):5571-5578. doi: 10.1016/j.vaccine.2016.09.041. Epub 2016 Sep 30.
3

本文引用的文献

1
A 2020 vision for vaccines against HIV, tuberculosis and malaria.针对艾滋病毒、结核病和疟疾疫苗的 2020 年愿景。
Nature. 2011 May 26;473(7348):463-9. doi: 10.1038/nature10124.
2
Rational design of HIV vaccines and microbicides: report of the EUROPRISE network annual conference 2010.HIV 疫苗和杀微生物剂的合理设计：EUROPRISE 网络 2010 年年度会议报告。
J Transl Med. 2011 Apr 12;9:40. doi: 10.1186/1479-5876-9-40.
3
Immunogenicity and protective efficacy against murine tuberculosis of a prime-boost regimen with BCG and a DNA vaccine expressing ESAT-6 and Ag85A fusion protein.
The evolution of poxvirus vaccines.
痘病毒疫苗的演变
Viruses. 2015 Apr 7;7(4):1726-803. doi: 10.3390/v7041726.
4
In silico design of a DNA-based HIV-1 multi-epitope vaccine for Chinese populations.针对中国人群的基于DNA的HIV-1多表位疫苗的计算机辅助设计
Hum Vaccin Immunother. 2015;11(3):795-805. doi: 10.1080/21645515.2015.1012017.
5
Generation and evaluation of clade C simian-human immunodeficiency virus challenge stocks.C组猿猴-人类免疫缺陷病毒攻击毒株的产生与评估
J Virol. 2015 Feb;89(4):1965-74. doi: 10.1128/JVI.03279-14. Epub 2014 Dec 3.
卡介苗与表达ESAT-6和Ag85A融合蛋白的DNA疫苗初免-加强方案对小鼠结核病的免疫原性和保护效力
Clin Dev Immunol. 2011;2011:617892. doi: 10.1155/2011/617892. Epub 2011 Feb 27.
4
Prime-boost immunization with poxvirus or adenovirus vectors as a strategy to develop a protective vaccine for HIV-1.以痘病毒或腺病毒载体进行初免-加强免疫接种，作为开发针对 HIV-1 的保护性疫苗的策略。
Expert Rev Vaccines. 2010 Sep;9(9):1055-69. doi: 10.1586/erv.10.106.
5
Heterologous Prime-Boost HIV-1 Vaccination Regimens in Pre-Clinical and Clinical Trials.临床前和临床试验中的异源初免-加强HIV-1疫苗接种方案。
Viruses. 2010 Feb 1;2(2):435-467. doi: 10.3390/v2020435.
6
Immunology and the elusive AIDS vaccine.免疫学与难以捉摸的艾滋病疫苗。
Nature. 2010 Mar 11;464(7286):224-31. doi: 10.1038/nature08898.
7
Comparative immunogenicity of subtype a Human Immunodeficiency Virus type 1 envelope exhibiting differential exposure of conserved neutralization epitopes.亚型 A 人类免疫缺陷病毒 1 型包膜的比较免疫原性，表现出保守中和表位的不同暴露。
J Virol. 2010 Mar;84(5):2573-84. doi: 10.1128/JVI.01687-09. Epub 2009 Dec 16.
8
Roadblocks in HIV research: five questions.艾滋病病毒研究中的障碍：五个问题
Nat Med. 2009 Aug;15(8):855-9. doi: 10.1038/nm0809-855.
9
Blocking and tackling HIV.抗击艾滋病毒。
Nat Med. 2009 Aug;15(8):841-2. doi: 10.1038/nm0809-841.
10
Differential neutralization of human immunodeficiency virus (HIV) replication in autologous CD4 T cells by HIV-specific cytotoxic T lymphocytes.HIV特异性细胞毒性T淋巴细胞对自体CD4 T细胞中人类免疫缺陷病毒（HIV）复制的差异性中和作用。
J Virol. 2009 Apr;83(7):3138-49. doi: 10.1128/JVI.02073-08. Epub 2009 Jan 21.